All In Biotech

Drug Trial Radar · NCT05668741

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

A Phase 1/2 Dose Escalation Study Evaluating the Safety, and Tolerability and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Feb 27, 2023

Primary completion

Apr 21, 2026

Study completion Sep 9, 2026

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
Collaborators
Moderna, Inc
First posted
Dec 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.

Conditions

  • Cystic Fibrosis

Interventions

  • VX-522 mRNA therapyDrug

    Oral inhalation using nebulizer.

  • IVADrug

    Tablet for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 Through Week 8 [SAD and MAD]

Locations

26 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham - Child Health Research Unit

    Birmingham, Alabama

  • Memorial Health Services on behalf of Long Beach Memorial Medical Center d/b/a Miller Children's Hospital Long Beach

    Long Beach, California

  • Stanford University - Palo Alto - Pulmonology

    Palo Alto, California

  • National Jewish Health

    Denver, Colorado

  • Clinical & Translational Science Unit (CTSU) - Pulmonology

    Kansas City, Kansas

  • PAREXEL International - Baltimore

    Baltimore, Maryland

  • The Johns Hopkins University - Johns Hopkins Hospital - Pulmonology

    Baltimore, Maryland

  • MGH - MGfC Pediatric Cystic Fibrosis Center

    Boston, Massachusetts

  • Boston Children's Hospital

    Boston, Massachusetts

  • University of Minnesota -Pulmonology

    Minneapolis, Minnesota

  • St. Louis Children's Hospital - Pulmonology

    St Louis, Missouri

  • UC Health Holmes Hospital

    Cincinnati, Ohio

  • Medical University of South Carolina - Pulmonology

    Charleston, South Carolina

  • University of Utah Hospital - Pulmonology

    Salt Lake City, Utah

  • The Alfred Hospital - Pulmonology

    Melbourne, Australia

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • University of Calgary Medical Clinic of the Foothills Medical Centre

    Calgary, Canada

  • IUCPQ Pavillon Recherche U-1771

    Québec, Canada

  • Ruhrlandklinik

    Essen, Germany

  • Karolinska University Hospital - Pulmonology

    Stockholm, Sweden

  • Papworth Hospital NHS Foundation Trust

    Cambridge, United Kingdom

  • Queen Elizabeth University Hospital - Pulmonology

    Glasgow, United Kingdom

  • Royal Brompton Hospital

    London, United Kingdom

  • Wythenshawe Hospital - OPD

    Manchester, United Kingdom

  • All Wales Adult Cystic Fibrosis Centre, University Hospital Llandough

    Penarth, United Kingdom

  • University Hospital Southampton NHS Fountion - Southampton General Hospital

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.